VEDAVYASA BILIYAR: Open Payments
NPI 1609814748 · NASHVILLE, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,209 in 52 payments from 14 companies in 2025. Trend: 2023 $228 · 2024 $483 · 2025 $1,209
Food & beverage: $1,209
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 11 | $191 |
| Neurocrine BioSciences, Inc. | 6 | $180 |
| Teva Pharmaceuticals USA, Inc. | 7 | $150 |
| E.R. Squibb & Sons, L.L.C. | 6 | $144 |
| Axsome Therapeutics, Inc. | 4 | $112 |
| Alkermes, Inc. | 4 | $97 |
| Janssen Pharmaceuticals, Inc | 4 | $87 |
| Vanda Pharmaceuticals Inc. | 2 | $77 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
Products named: INGREZZA, COBENFY, REXULTI, Auvelity, AUSTEDO XR, FANAPT, ARISTADA, CAPLYTA.
Industry payments across TN — which companies pay providers there.
